% | $
Quotes you view appear here for quick access.

Chelsea Therapeutics Internation Message Board

  • jakeddddddd jakeddddddd May 2, 2013 8:19 AM Flag

    Financials are out

    Imo great news! "In the first quarter, we made significant progress toward the commercialization of Northera(TM) (droxidopa) for the treatment of symptomatic Neurogenic Orthostatic Hypotension, a debilitating orphan condition that is greatly in need of alternative therapies," said Joseph G. Oliveto, Interim CEO of Chelsea. "Our team has navigated through the significant challenges of showing a symptomatic benefit in this difficult to treat disease state, and now, with updated guidance from the U.S. Food and Drug Administration, we have a regulatory path forward toward review and potential approval this year. We remain focused on resubmission of a New Drug Application for Northera in NOH." They still have plenty of $

    SortNewest  |  Oldest  |  Most Replied Expand all replies